摘要
目的探讨不同给药方式对晚期前列腺癌内分泌治疗(亮丙瑞林微球联合抗雄激素药物)的影响。方法选取安徽医科大学第三附属医院2018年1月至2019年4月收治的晚期前列腺癌患者34例,根据给药方式不同,分为持续性给药组(对照组)和间歇性给药组(观察组)各17例。观察比较1年内两组患者疗效、不良反应及各时间点前列腺特异性抗原(PSA)水平。结果治疗后观察组总缓解率高于对照组(P<0.05);两组不良反应发生率差异无统计学意义(P>0.05)。两组治疗后各个时间点(3,6,9,12月)PSA水平均显著低于治疗前(P<0.05),以及各时间点对照组PSA水平明显高于观察组(P<0.05);结论亮丙瑞林微球联合抗雄激素药物的两种给药方式均能明显降低晚期前列腺癌患者的血清PSA,而间歇性给药的临床疗效明显优于持续性给药,且安全性好。
Objective To explore the effects of different administration methods(Leuprorelin Acetate Microspheres and anti-androgen medications)in the endocrinotherapy of advanced prostate cancer.Methods A total of 34 patients with advanced prostate cancer admitted to the third affiliated hospital of Anhui Medical University from January 2018 to April 2019 were selected.The patients were divided into the continuous administration group(control group)and the intermittent administration group(observation group)according to the different ways of administration.The efficacy,adverse reactions and the level of prostate-specific antigen(PSA)at each time point in the two groups in 1 year were compared.Results The total remission rate of the observation group was higher than that in the control group after treatment(P<0.05);there was no significant statistical difference in the incidence of adverse reaction between the two groups(P>0.05).The PSA level of the two groups at each point of time(3,6,9,12 months)after treatment was significantly lower than that before treatment(P<0.05),and the PSA level of the control group at each point of time was significantly higher than that in the observation group(P<0.05).Conclusion The two administration methods of leurelin microspheres combined with anti-androgen agents can significantly reduce the serum PSA in patients with advanced prostate cancer,while the clinical effect of intermittent administration is significantly better than that of continuous administration with better safety.
作者
王佳
秦侃
邵峰
王钰
Wang Jia;Qin Kan;Shao Feng;Wang Yu(Department of Pharmacy,the Third Hospital Affiliated to Anhui Medical University,Hefei 230061,China;不详)
出处
《中国临床保健杂志》
CAS
2020年第5期701-703,共3页
Chinese Journal of Clinical Healthcare
基金
安徽省“十三五”医疗卫生重点专科建设项目(皖卫教科[2017]30号)。
关键词
前列腺肿瘤
投药途径
治疗结果
Prostatic neoplasms
Drug administration routes
Treatment outcome
